REPROGRAMMING OF GENETICALLY ENGINEERED PRIMARY IMMUNE CELLS

摘要

The invention pertains to the field of adaptive cell immunotherapy and provides with methods for producing hematoipoietic engineered cells lines by reprogramming primary cells that have been genetically engineered. By engineering primary cells before their reprogramming into multipotent cells, the cells can be tested or even screen for their sought therapeutical properties. The multipotent cells obtainable by these methods offer a renewable source for the production of "off the shelf" therapeutic cells that can be differentiated in vitro or in vivo into immune effector cells.